Cohen Investment Advisors LLC Purchases 1,033 Shares of Eli Lilly and Company (NYSE:LLY)

Cohen Investment Advisors LLC increased its holdings in Eli Lilly and Company (NYSE:LLY) by 9.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,483 shares of the company’s stock after buying an additional 1,033 shares during the quarter. Eli Lilly and Company comprises 5.8% of Cohen Investment Advisors LLC’s portfolio, making the stock its largest holding. Cohen Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $8,933,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Lipe & Dalton acquired a new stake in Eli Lilly and Company in the fourth quarter worth approximately $26,000. Core Wealth Advisors Inc. lifted its holdings in shares of Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares during the period. Tidemark LLC bought a new position in Eli Lilly and Company during the fourth quarter valued at about $29,000. Redmont Wealth Advisors LLC acquired a new position in Eli Lilly and Company during the first quarter worth about $40,000. Finally, Frank Rimerman Advisors LLC bought a new stake in Eli Lilly and Company in the fourth quarter worth about $37,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 8,848 shares of the business’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $915.31, for a total value of $8,098,662.88. Following the completion of the sale, the insider now directly owns 97,299,772 shares in the company, valued at approximately $89,059,454,309.32. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 8,848 shares of the company’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $915.31, for a total transaction of $8,098,662.88. Following the completion of the sale, the insider now directly owns 97,299,772 shares in the company, valued at $89,059,454,309.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the transaction, the chief accounting officer now owns 7,130 shares in the company, valued at $5,842,821.10. The disclosure for this sale can be found here. Insiders have sold a total of 858,742 shares of company stock worth $735,573,781 over the last three months. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. BMO Capital Markets restated an “outperform” rating and set a $1,001.00 price objective on shares of Eli Lilly and Company in a research report on Wednesday. JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. Citigroup upped their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Finally, TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $812.72.

Eli Lilly and Company Stock Down 0.9 %

Shares of Eli Lilly and Company stock traded down $8.61 during trading on Thursday, hitting $898.10. 3,078,367 shares of the stock traded hands, compared to its average volume of 2,667,176. The stock has a market cap of $853.56 billion, a P/E ratio of 132.27, a PEG ratio of 1.98 and a beta of 0.41. The company has a fifty day moving average price of $824.60 and a two-hundred day moving average price of $746.69. Eli Lilly and Company has a twelve month low of $434.34 and a twelve month high of $918.50. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.62 earnings per share. Equities research analysts predict that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.58%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s payout ratio is 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.